

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 August 2007 (30.08.2007)

PCT

(10) International Publication Number
WO 2007/098384 A2

(51) International Patent Classification:
C07D 313/08 (2006.01) *A61K 31/335* (2006.01)
C07D 493/10 (2006.01) *A61P 15/18* (2006.01)

(74) Agents: **JOHNSON, Phillip, S.** et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).

(21) International Application Number:
PCT/US2007/062280

(22) International Filing Date:
16 February 2007 (16.02.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/774,348 17 February 2006 (17.02.2006) US

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHEN, Ningyi** [CN/US]; 341 Minuteman Drive, Collegeville, Pennsylvania 19426 (US). **JAIN, Nareshkumar F.** [US/US]; Johnson & Johnson Pharmaceutical Research & Development, LLC, 665 Stockton Drive, Exton, Pennsylvania 19341 (US). **SUI, Zhihua** [US/US]; Johnson & Johnson Pharmaceutical Research and Development, LLC, 665 Stockton Drive, Exton, Pennsylvania 19341 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TETRACYCLIC STEROID DERIVATIVES USEFUL AS PROGESTERONE RECEPTOR MODULATORS

(57) Abstract: The present invention is directed to tetracyclic steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by a progesterone or glucocorticoid receptor.



PRD2637WOPCT

TETRACYCLIC STEROID DERIVATIVES USEFUL AS PROGESTERONE RECEPTOR MODULATORS

FIELD OF THE INVENTION

5 The present invention is directed to tetracyclic steroid derivatives,
pharmaceutical compositions containing them and their use in the treatment of
disorders and conditions modulated by a progesterone or glucocorticoid
receptor. More particularly, the compounds of the present invention are useful
in the treatment of disorders including, but not limited to, secondary
10 amenorrhea; dysfunctional bleeding; uterine leiomyomata; endometriosis;
polycystic ovary syndrome; carcinomas and adenocarcinomas of the
endometrium, ovary, breast, colon and / or prostate, Type II diabetes mellitus,
impaired oral glucose tolerance, elevated blood glucose levels and Syndrome
X. The compounds of the present invention are further useful as
15 contraceptives and for the minimization of side effects of cyclic menstrual
bleeding (e.g. for the treatment of premenstrual syndrome) and for
contraception.

BACKGROUND OF THE INVENTION

20 Intracellular receptors are a class of structurally related proteins involved
in the regulation of gene proteins. Steroid receptors are a subset of these
receptors, including the progesterone receptors (PR), androgen receptors (AR),
estrogen receptors (ER), glucocorticoid receptors (GR) and mineralocorticoid
receptors (MR). Regulation of a gene by such factors requires the intracellular
25 receptor and corresponding ligands, which has the ability to selectively bind to
the receptor in a way that affects gene transcription.

 Progesterone receptor modulators (progestagens) are known to play an
important role in mammalian development and homeostasis. Progesterone is
30 known to be required for mammary gland development, ovulation and the
maintenance of pregnancy. Currently, steroidal progestin agonists and
antagonists are clinically approved for contraception, hormone replacement
therapy (HRT) and therapeutic abortion. Moreover, there is good preclinical

PRD2637WOPCT

and clinical evidence for the value of progestin antagonists in treating endometriosis, uterine leiomyomata (fibroids), dysfunctional uterine bleeding and breast cancer.

5 The current steroidal progestagens have been proven to be quite safe and are well tolerated. Sometimes, however, side effects (e.g. breast tenderness, headaches, depression and weight gain) have been reported that are attributed to these steroidal progestagens, either alone or in combination with estrogenic compounds.

10

 Steroidal ligands for one receptor often show cross-reactivity with other steroidal receptors. As an example, many progestagens also bind to glucocorticoid receptor. Non-steroidal progestagens have no molecular similarity with steroids and therefore one might also expect differences in physicochemical properties, pharmacokinetic (PK) parameters, tissue distribution (e.g. CNS versus peripheral) and, more importantly, non-steroidal progestagens may show no/less cross-reactivity to other steroid receptors. Therefore, non-steroidal progestagens will likely emerge as major players in reproductive pharmacology in the foreseeable future.

20

 It was known that progesterone receptor existed as two isoforms, full-length progesterone receptor isoform (PR-B) and its shorter counterpart (PR-A). Recently, extensive studies have been implemented on the progesterone receptor knockout mouse (PRKO, lacking both the A- and B-forms of the receptors), the mouse knocking out specifically for the PR-A isoform (PRAKO) and the PR-B isoform (PRBKO). Different phenotypes were discovered for PRKO, PRAKO and PRBKO in physiology studies in terms of fertility, ovulation uterine receptivity, uterine proliferation, proliferation of mammary gland, sexual receptivity in female mice, sexual activity in male mice and infanticide tendencies in male mice. These findings provided insights for synthetic chemists to construct not only selective progesterone receptor modulator (SPRM), but also PR-A or PR-B selective progesterone receptor modulator.

30

PRD2637WOPCT

Progesterone plays a major role in reproductive health and functioning. Its effects on, for example, the uterus, breast, cervix and hypothalamic-pituitary unit are well established. The actions of progesterone as well as progesterone antagonists are mediated by the progesterone receptor (PR). In the target cell,

5 progesterone produces a dramatic change in conformation of the PR that is associated with transforming the PR from a non-DNA binding form to one that will bind to DNA. This transformation is accompanied by a loss of associated heat shock proteins and dimerization. The activated PR dimer then binds to specific DNA sequences within the promoter region of progesterone responsive

10 genes. The agonist-bound PR is believed to activate transcription by associating with coactivators, which act as bridging factors between the receptor and the general transcription machinery. This is followed by increases in the rate of transcription producing agonist effects at the cellular and tissue levels. These progesterone receptor ligands exhibit a spectrum of activity

15 ranging from pure antagonists to mixed agonists/antagonists.

In 1982, the discovery of compounds that bind to the progesterone receptor, antagonize the effects of progesterone receptor and antagonize the effects of progesterone was announced. Although compounds such as

20 estrogens and certain enzyme inhibitors can prevent the physiological effects of endogenous progesterone, the term "antiprogesterone" is confined to those compounds that bind to the progesterone receptor. A report from the Institute of Medicine (Donaldson, Molly S.; Dorflinger, L.; Brown, Sarah S.; Benet, Leslie Z., Editors, *Clinical Applications of Mifepristone (RU 486) and Other*

25 *antiprogesterones*, Committee on antiprogesterones: Assessing the science, Institute of medicine, National Academy Press, 1993) summarized a number of medical conditions related to the effect of antiprogesterones. In view of the pivotal role that progesterone plays in reproduction, it is not surprising that antiprogesterones could play a part in fertility control, including contraception, menses induction and

30 medical termination of pregnancy, but there are many other potential uses that have been supported by small clinical or preclinical studies, such as labor and delivery; treatment of uterine leiomyomas (fibroids), treatment of endometriosis; HRT; breast cancers; male contraception, etc.

PRD2637WOPCT

The effects and uses of progesterone agonists have been well established. In addition, it has been recently shown that certain compounds structurally related to the known antiprogestins have agonist activity in certain biological systems (e.g., the classical progestin effects in the estrogen-primed immature rabbit uterus; cf. C. E. Cook et al., *Life Sciences*, 52, 155-162 (1993)). Such compounds are partial agonists in human cell-derived receptor systems, where they bind to a site distinct from both the progestin and antiprogestin sites (Wagner et al., *Proc. Natl. Acad. Sci.*, 93, 8739-8744 (1996)). Thus the general class of antiprogestins can have subclasses, which may vary in their clinical profiles.


Compounds which mimic some of the effects of progesterone (agonists), antagonize these effects (antagonists, antiprogestins) or exhibit mixed effects (partial agonists or mixed agonist/antagonist), known as progesterone receptor modulators (PRMs) can be useful in treating a variety of disease states and conditions. PR agonists have been used in female contraceptives and in postmenopausal hormone therapy. Recent studies in women and non-human primates show that PR antagonists may also have potential as contraceptive agents and for the treatment of various gynecological and obstetric diseases, including fibroids, endometriosis and, possibly, hormone-dependent cancers. Clinically available PR agonists and antagonists are steroidal compounds and often cause various side effects due to their functional interaction with other steroid receptors. Recently, numerous receptor-selective non-steroidal PR agonists and antagonists have emerged. Non-steroidal PR antagonists, being structurally distinct from the steroid class, may have greater potential for selectivity against other steroid receptors.

30

PRD2637WOPCT

SUMMARY OF THE INVENTION

The present invention is directed to compounds of formula (I)




wherein

- 5 R^1 is selected from the group consisting of $-NR^A R^B$, $-O-R^A$, $-S-R^A$ and $-SO_2-R^A$; wherein R^A and R^B are each independently selected from the group consisting of hydrogen and C_{1-4} alkyl;

- R^2 is selected from the group consisting of C_{1-4} alkyl, $-C_{1-4}$ alkyl-OH, halogenated C_{1-4} alkyl, C_{2-4} alkenyl, $-C_{2-4}$ alkenyl-OH, $-C_{2-4}$ alkenyl- CF_3 , C_{2-4} alkynyl, $-C_{2-4}$ alkynyl- CF_3 , $-C_{2-4}$ alkynyl-phenyl, $-C(O)-C_{2-4}$ alkyl, $-C(O)-C_{2-4}$ alkenyl and $-C(O)-phenyl$; wherein the phenyl, whether alone or as part of a substituent group, is optionally substituted with one to two substituents independently selected from the group consisting of halogen, C_{1-4} alkyl, fluorinated C_{1-4} alkyl, C_{1-4} alkoxy, fluorinated C_{1-4} alkoxy, cyano, nitro, amino, C_{1-4} alkylamino and $di(C_{1-4}alkyl)amino$;
- 10 R^3 is $-OH$;
- 15 alternatively, R^2 and R^3 are taken together with the carbon atom to which they are bound to form $C(O)$ or 2-(3-methylene-tetrahydro-furanyl);
- 20 and pharmaceutically acceptable salts, esters and prodrugs thereof.

The present invention is further directed to compounds of formula (II)



PRD2637WOPCT

wherein

R¹ is selected from the group consisting of -NR^AR^B, -O-R^A, -S-R^A and -SO₂-R^A; wherein R^A and R^B are each independently selected from the group consisting of hydrogen and C₁₋₄alkyl;

5

R² is selected from the group consisting of C₁₋₄alkyl, -C₁₋₄alkyl-OH, halogenated C₁₋₄alkyl, C₂₋₄alkenyl, -C₂₋₄alkenyl-OH, -C₂₋₄alkenyl-CF₃, C₂₋₄alkynyl, -C₂₋₄alkynyl-CF₃, -C₂₋₄alkynyl-phenyl, -C(O)-C₂₋₄alkyl, -C(O)-C₂₋₄alkenyl and -C(O)-phenyl; wherein the phenyl, whether alone or as part of a

10 substituent group, is optionally substituted with one to two substituents independently selected from the group consisting of halogen, C₁₋₄alkyl, fluorinated C₁₋₄alkyl, C₁₋₄alkoxy, fluorinated C₁₋₄alkoxy, cyano, nitro, amino, C₁₋₄alkylamino and di(C₁₋₄alkyl)amino;

and pharmaceutically acceptable salts, esters and prodrugs thereof.

15

Illustrative of the invention is a pharmaceutical composition which comprising a pharmaceutically acceptable carrier and the product prepared according to the process described herein. An illustration of the invention is a pharmaceutical composition made by mixing the product prepared according to

20 the process described herein and a pharmaceutically acceptable carrier.

Illustrating the invention is a process for making a pharmaceutical composition comprising mixing the product prepared according to the process described herein and a pharmaceutically acceptable carrier.

25

Exemplifying the invention are methods of treating a disorder mediated by at least one progesterone receptor comprising administering to a subject in need thereof a therapeutically effective amount of any of the compounds or pharmaceutical compositions described above.

30

In another embodiment, the compounds of the present invention are useful for the treatment of disorders mediated by at least one glucocorticoid receptor comprising administering to a subject in need thereof a therapeutically

PRD2637WOPCT

effective amount of any of the compounds or pharmaceutical compositions described above.

In another embodiment, the compounds of the present invention are
5 useful for the treatment of a disorder selected from the group consisting of
secondary amenorrhea; dysfunctional bleeding; uterine leiomyomata;
endometriosis; polycystic ovary syndrome; carcinoma of the endometrium,
carcinoma of the ovary, carcinoma of the breast, carcinoma of the colon,
carcinoma of the prostate, adenocarcinomas of the ovary, adenocarcinomas of
10 the breast, adenocarcinomas of the colon, adenocarcinomas of the prostate,
side effects of cyclic menstrual bleeding or for contraception; comprising
administering to a subject in need thereof a therapeutically effective amount of
any of the compounds or pharmaceutical compositions described above.


15 In another embodiment, the compounds of the present invention are
useful for the treatment of a disorder selected from the group consisting of
Type II diabetes mellitus, impaired oral glucose tolerance, elevated blood
glucose levels and Syndrome X; comprising administering to a subject in need
thereof a therapeutically effective amount of any of the compounds or
20 pharmaceutical compositions described above.

Another example of the invention is the use of any of the compounds
described herein in the preparation of a medicament for treating of a
progesterone or glucocorticoid receptor mediated disorder, (treating a disorder
25 selected from (a) secondary amenorrhea; (b) dysfunctional bleeding; (c) uterine
leiomyomata; (d) endometriosis; (e) polycystic ovary syndrome; (f) carcinoma
of the endometrium, (g) carcinoma of the ovary, (h) carcinoma of the breast, (i)
carcinoma of the colon, (j) carcinoma of the prostate, (k) adenocarcinomas of
the ovary, (l) adenocarcinomas of the breast, (m) adenocarcinomas of the
30 colon, (n) adenocarcinomas of the prostate, (o) side effects of cyclic menstrual
bleeding, (p) Type II diabetes mellitus, (q) impaired oral glucose tolerance, (r)
elevated blood glucose levels, (s) Syndrome X or (t) for contraception, in a
subject in need thereof) in a subject in need thereof.

PRD2637WOPCT

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to compounds of formula (I) and compound of formula (II)



wherein R^1 , R^2 and R^3 are as herein defined. The compounds of formula (I) of the present invention are useful as progesterone receptor modulators and / or glucocorticoid receptor modulators, useful in the treatment of disorders including, but not limited to, secondary amenorrhea; dysfunctional bleeding; uterine leiomyomata; endometriosis; polycystic ovary syndrome; carcinoma of the endometrium, carcinoma of the ovary, carcinoma of the breast, carcinoma of the colon, carcinoma of the prostate, adenocarcinomas of the ovary, adenocarcinomas of the breast, adenocarcinomas of the colon, adenocarcinomas of the prostate, side effects of cyclic menstrual bleeding, Type II diabetes mellitus, impaired oral glucose tolerance, elevated blood glucose levels and Syndrome X or for contraception.

10

15

In an embodiment of the present invention, R^1 is selected from the group consisting of $NR^A R^B$, $-OR^A$, $-SR^A$ and $-SO_2-R^A$; wherein R^A and R^B are each independently selected from the group consisting of hydrogen and C_{1-2} alkyl.

20

PRD2637WOPCT

In another embodiment of the present invention, R^1 is selected from the group consisting of $NR^A R^B$, $-OR^A$, $-SR^A$ and $-SO_2-R^A$; wherein R^A and R^B are each independently selected from C_{1-2} alkyl.

- 5 In another embodiment of the present invention, R^1 is selected from the group consisting of $-SR^A$; wherein R^A is selected from C_{1-3} alkyl, preferably methylthio.

- 10 In another embodiment of the present invention, R^1 is selected from the group consisting of dimethylamino, methoxy, methylthio and methylsulfonyl. In another embodiment of the present invention, R^1 is selected from the group consisting of dimethylamino, methoxy and methylthio.

- 15 In an embodiment of the present invention, R^2 is selected from the group consisting of C_{1-4} alkyl, fluorinated C_{1-4} alkyl, $-C_{1-4}$ alkyl-OH, C_{2-4} alkenyl, $-C_{2-4}$ alkenyl-OH, $-C_{2-4}$ alkenyl- CF_3 , C_{2-4} alkynyl, $-C_{2-4}$ alkynyl- CF_3 , $-C_{2-4}$ alkynyl-phenyl, $-C(O)-C_{2-4}$ alkyl, and $-C(O)-C_{2-4}$ alkenyl; wherein the phenyl is optionally substituted with one to two substituents independently selected from the group consisting of halogen, C_{1-4} alkyl, fluorinated C_{1-4} alkyl, C_{1-4} alkoxy and fluorinated
20 C_{1-4} alkoxy.

- In another embodiment of the present invention, R^2 is selected from the group consisting of fluorinated C_{1-3} alkyl, C_{2-4} alkenyl, $-C_{2-4}$ alkenyl-OH, C_{2-4} alkynyl; $-C_{2-4}$ alkynyl- CF_3 , $-C_{2-4}$ alkynyl-phenyl, and $-C(O)-C_{2-4}$ alkenyl; wherein
25 the phenyl is optionally substituted with one to two substituents independently selected from the group consisting of halogen, C_{1-4} alkyl and fluorinated C_{1-3} alkyl.

- In another embodiment of the present invention, R^2 is selected from the group consisting of $-CF_2-CF_3$, $-CCH$, $-CC-CH_3$ and $-CC$ -phenyl; wherein the phenyl is optionally substituted with one to two substituent groups
30 independently selected from fluoro or C_{1-4} alkyl.

PRD2637WOPCT

In another embodiment of the present invention, R^2 is selected from the group consisting of $-\text{CC-phenyl}$; wherein the phenyl is optionally substituted with one to two substituents independently selected from the group consisting of halogen, C_{1-4} alkyl and fluorinated C_{1-3} alkyl.

5

In another embodiment of the present invention, R^2 is selected from the group consisting of $-\text{CF}_2-\text{CF}_3$, $-\text{CH}(\text{=CH}_2)-\text{CH}_3$, $-\text{CH}_2-\text{CH}=\text{CH}_2$, $-\text{CCH}$, $-\text{CC-CH}_3$, $-\text{CC-CF}_3$, $-\text{CC-phenyl}$, $-\text{CC-(4-trifluoromethyl-phenyl)}$, $-\text{CC-(4-t-butyl-phenyl)}$, $-\text{CC-(2-fluor-phenyl)}$, $-\text{CC-(3-fluoro-phenyl)}$, $-\text{CC-(4-fluoro-phenyl)}$, $-\text{CC-(3,5-difluoro-phenyl)}$, $-\text{CH}(\text{=CH}_2)-\text{CH}_2-\text{CH}_2-\text{OH}$ and $-\text{C(O)-CH=CH}_2$.

10

In another embodiment of the present invention, R^2 is selected from the group consisting of $-\text{CF}_2-\text{CF}_3$, $-\text{CH}(\text{=CH}_2)-\text{CH}_3$, $-\text{CCH}$, $-\text{CC-phenyl}$, $-\text{CC-(2-fluoro-phenyl)}$, $-\text{CC-(4-fluoro-phenyl)}$ and $-\text{CC-(4-trifluoromethyl-phenyl)}$. In another embodiment of the present invention, R^2 is selected from the group consisting of $-\text{CF}_2-\text{CF}_3$, $-\text{CH}(\text{=CH}_2)-\text{CH}_3$, $-\text{CCH}$ and $-\text{CC-CH}_3$.

15

In an embodiment of the present invention, R^2 and R^3 are taken together with the carbon atom to which they are bound to form C(O) or 2-(3-methylene-tetrahydro-furanyl). In another embodiment of the present invention, R^2 and R^3 are taken together with the carbon atom to which they are bound to form 2-(3-methylene-tetrahydro-furanyl).

20

In another embodiment of the present invention is any single compound or subset of compounds selected from the representative compounds listed in Tables 1 below.

25

Additional embodiments of the present invention, include those wherein the substituents selected for one or more of the variables defined herein (i.e., R^1 , R^2 and R^3) are independently selected to be any individual substituent or any subset of substituents selected from the complete list as defined herein.

30

PRD2637WOPCT






Representative compounds of the present invention are as listed in Table 1.

PRD2637WOPCT






Table 1: Representative Compounds of Formula (I) and Formula (II)

Compound No.	Structure
1	 <chem>CN(C)c1ccc(cc1)[C@H]2O[C@@H](C=C)[C@H](C)[C@H]2C3=C(C(=O)C=C4C=CC(=O)CC4)C=C(C)C3</chem>
2	 <chem>CSc1ccc(cc1)[C@H]2O[C@@H](C=C)[C@H](C)[C@H]2C3=C(C(=O)C=C4C=CC(=O)CC4)C=C(C)C3</chem>
3	 <chem>COc1ccc(cc1)[C@H]2O[C@@H](C=C)[C@H](C)[C@H]2C3=C(C(=O)C=C4C=CC(=O)CC4)C=C(C)C3</chem>
4	 <chem>CN(C)c1ccc(cc1)[C@H]2O[C@@H](C#C)[C@H](C)[C@H]2C3=C(C(=O)C=C4C=CC(=O)CC4)C=C(C)C3</chem>






PRD2637WOPCT

5	
6	
7	
9	
10	

PRD2637WOPCT

11	
12	
13	
14	
15	






PRD2637WOPCT

16	 Chemical structure 16: A complex polycyclic molecule. It features a p-methoxyphenyl group attached to a ring system. The ring system includes a ketone and a terminal phenylethynyl group. Stereochemistry is indicated as (R,R,R,E,Z).
17	 Chemical structure 17: A complex polycyclic molecule. It features a p-methoxyphenyl group attached to a ring system. The ring system includes a ketone and a terminal vinyl group. Stereochemistry is indicated as (R,R,R,E,Z).
18	 Chemical structure 18: A complex polycyclic molecule. It features a p-methoxyphenyl group attached to a ring system. The ring system includes a ketone and a terminal vinyl group. Stereochemistry is indicated as (S,R,R,E,Z).
19	 Chemical structure 19: A complex polycyclic molecule. It features a p-methoxyphenyl group attached to a ring system. The ring system includes a ketone and a terminal trifluoromethyl group. Stereochemistry is indicated as (R,R,R,E,Z).
20	 Chemical structure 20: A complex polycyclic molecule. It features a p-methoxyphenyl group attached to a ring system. The ring system includes a ketone and a terminal trifluoromethyl group. Stereochemistry is indicated as (S,R,R,E,Z).

PRD2637WOPCT

21	Chemical structure 21: A complex polycyclic molecule. It features a p-methoxyphenyl group attached to a ring system. The ring system includes a (Z)-enone and a (R)-hydroxyalkyne side chain. The stereochemistry is indicated by (R) and (Z) labels.
22	Chemical structure 22: A complex polycyclic molecule. It features a p-methoxyphenyl group attached to a ring system. The ring system includes a (Z)-enone and a (R)-hydroxyalkyne side chain. The stereochemistry is indicated by (R) and (Z) labels.
23	Chemical structure 23: A complex polycyclic molecule. It features a p-methoxyphenyl group attached to a ring system. The ring system includes a (Z)-enone and a (R)-hydroxyalkyne side chain. The stereochemistry is indicated by (R) and (Z) labels.
24	Chemical structure 24: A complex polycyclic molecule. It features a p-methoxyphenyl group attached to a ring system. The ring system includes a (Z)-enone and a (R)-hydroxyalkyne side chain. The stereochemistry is indicated by (R) and (Z) labels.
25	Chemical structure 25: A complex polycyclic molecule. It features a p-methoxyphenyl group attached to a ring system. The ring system includes a (Z)-enone and a (R)-hydroxyalkyne side chain. The stereochemistry is indicated by (R) and (Z) labels.


PRD2637WOPCT

26	
27	
28	
29	
30	

PRD2637WOPCT

31	Chemical structure 31: A complex polycyclic molecule. It features a dimethylaminophenyl group attached to a ring system. The ring system includes a ketone group and a hydroxyl group. Stereochemistry is indicated with (R), (R), (R), (E), and (Z) labels.
32	Chemical structure 32: Similar to 31, but with a fluorophenyl group instead of a phenyl group.
33	Chemical structure 33: Similar to 31, but with a 4-fluorophenyl group.
34	Chemical structure 34: Similar to 31, but with a 4-fluorophenyl group and a different stereochemistry for the hydroxyl group.
35	Chemical structure 35: Similar to 31, but with a 3,5-difluorophenyl group.

PRD2637WOPCT



As used herein, “**halogen**” shall mean chlorine, bromine, fluorine and iodine.

- 5 As used herein, the term “**alkyl**” whether used alone or as part of a substituent group, include straight and branched chains. For example, alkyl radicals include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl and the like. Unless otherwise noted, “**C₁₋₄alkyl**” shall mean a carbon chain composition of 1-4 carbon atoms.

10

As used herein, the term “**alkenyl**” whether used alone or as part of a substituent group, include straight and branched chains comprising at least one unsaturated double bond (preferably one to two, more preferably one unsaturated double bond). For example, alkenyl radicals include --CH=CH_2 , 2-propenyl, 3-propenyl, 2-butenyl, 3-butenyl, and the like. Unless otherwise

15 noted, “**C₁₋₄alkenyl**” shall mean an alkenyl carbon chain composition of 1-4 carbon atoms.

- As used herein, the term “**alkynyl**” whether used alone or as part of a substituent group, include straight and branched chains. For example, alkynyl
- 20

PRD2637WOPCT

radicals include $\text{-C}\equiv\text{CH}$, 2-propynyl, 3-propynyl, 2-butynyl, 3-butynyl, and the like. Unless otherwise noted, "**C₁₋₄alkynyl**" shall mean an alkynyl carbon chain composition of 1-4 carbon atoms.

5 As used herein, unless otherwise noted, the term "**halogenated C₁₋₄alkyl**" shall mean any C₁₋₄alkyl group as defined above substituted with at least one halogen atom, preferably substituted with a least one fluoro atom. Suitable examples include but are not limited to -CF_3 , $\text{-CH}_2\text{-CF}_3$, $\text{-CF}_2\text{-CF}_2\text{-CF}_2\text{-CF}_3$, and the like.

10

 As used herein, unless otherwise noted, the term "**fluorinated C₁₋₄alkyl**" shall mean any C₁₋₄alkyl group as defined above substituted with at least one fluorine atom, preferably substituted with a least one fluoro atom. Suitable examples include but are not limited to -CF_3 , $\text{-CH}_2\text{-CF}_3$, $\text{-CF}_2\text{-CF}_2\text{-CF}_2\text{-CF}_3$, and the like.

15

 As used herein, unless otherwise noted, "**alkoxy**" shall denote an oxygen ether radical of the above described straight or branched chain alkyl groups. For example, methoxy, ethoxy, n-propoxy, sec-butoxy, t-butoxy, n-hexyloxy and the like.

20

 As used herein, unless otherwise noted, the term "**halogenated C₁₋₄alkoxy**" shall mean any C₁₋₄alkoxy group as defined above substituted with at least one halogen atom, preferably substituted with a least one fluoro atom. Suitable examples include but are not limited to -OCF_3 , $\text{-OCH}_2\text{-CF}_3$, $\text{-OCF}_2\text{-CF}_2\text{-CF}_2\text{-CF}_3$, and the like.

25

 As used herein, unless otherwise noted, the term "**fluorinated C₁₋₄alkoxy**" shall mean any C₁₋₄alkoxy group as defined above substituted with at least one fluorine atom, preferably substituted with a least one fluoro atom. Suitable examples include but are not limited to -OCF_3 , $\text{-OCH}_2\text{-CF}_3$, $\text{-OCF}_2\text{-CF}_2\text{-CF}_2\text{-CF}_3$, and the like.

30

PRD2637WOPCT

As used herein, the notation “*” shall denote the presence of a stereogenic center.

- When a particular group is "**substituted**" (e.g., phenyl, aryl, heterocycloalkyl, heteroaryl), that group may have one or more substituents, preferably from one to five substituents, more preferably from one to three substituents, most preferably from one to two substituents, independently selected from the list of substituents.
- 10 With reference to substituents, the term "**independently**" means that when more than one of such substituents is possible, such substituents may be the same or different from each other.

- To provide a more concise description, some of the quantitative expressions given herein are not qualified with the term "**about**". It is understood that whether the term "about" is used explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including approximations due to the experimental and/or measurement conditions for such given value.
- 15
- 20

Abbreviations used in the specification, particularly the Schemes and Examples, are as follows:

DCE	=	Dichloroethane
DMF	=	N,N-Dimethylformamide
DMSO	=	Dimethylsulfoxide
Et ₃ N	=	Triethylamine
EtOAc	=	Ethyl acetate
EtOH	=	Ethanol
FBS	=	Fetal Bovine Serum
HPLC	=	High Pressure Liquid Chromatography
MeOH	=	Methanol
n-BuLi	=	n-Butyl Lithium

PRD2637WOPCT

NMO	=	4-Methylmorpholine N-oxide
PR	=	Progesterone Receptor
TBS	=	tert-Butyldimethylsilyl
TBSCl	=	tert-Butyldimethylchlorosilane
TBSOTf	=	tert-Butyldimethylsilyl trifluoromethanesulphonate
TES	=	Triethylsilyl
Tf	=	Triflate (i.e. $-O-SO_2-CF_3$)
Tf ₂ O	=	Triflic Anhydride
THF	=	Tetrahydrofuran
TIPS	=	Triisopropylsilyl
TsCl	=	Tosic chloride
TsOH	=	Tosic acid

As sued herein, unless otherwise noted, the term “**disorder mediated by at least one progesterone receptor**” shall include any disorder whose symptoms and / or underlying cause may be mediated, treated or prevented by the agonism or antagonism of at least one progesterone receptor. Suitable examples include, butt are not limited secondary amenorrhea; dysfunctional bleeding; uterine leiomyomata; endometriosis; polycystic ovary syndrome; carcinoma of the endometrium, carcinoma of the ovary, carcinoma of the breast, carcinoma of the colon, carcinoma of the prostate, adenocarcinomas of the ovary, adenocarcinomas of the breast, adenocarcinomas of the colon, adenocarcinomas of the prostate, side effects of cyclic menstrual bleeding, and the like. Compounds of the present invention which modulate at least one progesterone receptor are further useful as contraceptives.

As used herein, unless otherwise noted, the term “**disorder mediated by at least one glucocorticoid receptor**” shall include any disorder whose symptoms and / or underlying cause may be mediated, treated or prevented by the agonism or antagonism of at least one progesterone receptor. Suitable examples include, butt are not limited Type II diabetes mellitus, impaired oral glucose tolerance, elevated glucose levels, Syndrome X, and the like.

PRD2637WOPCT

The term “**subject**” as used herein, refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.

5 The term “**therapeutically effective amount**” as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.

10

As used herein, the term “**composition**” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.


15

Where the compounds according to this invention have at least one **chiral center**, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures
20 thereof are encompassed within the scope of the present invention. Preferably, wherein the compound is present as an enantiomer, the enantiomer is present at an enantiomeric excess of greater than or equal to about 80%, more preferably, at an enantiomeric excess of greater than or equal to about 90%, more preferably still, at an enantiomeric excess of greater than or equal to
25 about 95%, more preferably still, at an enantiomeric excess of greater than or equal to about 98%, most preferably, at an enantiomeric excess of greater than or equal to about 99%. Similarly, wherein the compound is present as a diastereomer, the diastereomer is present at an diastereomeric excess of greater than or equal to about 80%, more preferably, at an diastereomeric
30 excess of greater than or equal to about 90%, more preferably still, at an diastereomeric excess of greater than or equal to about 95%, more preferably still, at an diastereomeric excess of greater than or equal to about 98%, most preferably, at an diastereomeric excess of greater than or equal to about 99%.


PRD2637WOPCT

Furthermore, some of the crystalline forms for the compounds of the present invention may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds of the present invention may form solvates with water (i.e., hydrates) or common
5 organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.

Compounds of formula (I) of the present invention may be prepared according to the processes outlined in Schemes 1 and 2 below. Compounds of
10 formula (I) wherein R³ is -OH may be prepared according to the procedure outlined in Scheme 1 below.



PRD2637WOPCT



5

Scheme 1

Accordingly, a suitably substituted compound of formula (X), a known compound or compound prepared by known methods, is reacted with a suitably selected oxidizing agent such as DMSO/(COCl)₂/Et₃N (swern Oxidation), KMnO₄, CrO₃, and the like, in an organic solvent such as methylene chloride, CHCl₃, and the like, at a temperature in the range of from about -78°C to about 40°C, to yield the corresponding compound of formula (XI).

10

PRD2637WOPCT

The compound of formula (X) is reacted with ethane-1,2-diol, a known compound, in the presence of a such as ethylorthoformate, methyl ortho formate, and the like, in the presence of an acid such as TsOH, H₂SO₄, HCl, and the like, in an organic solvent such as THF, dioxane, diethyl ether and the
5 like, to yield the corresponding compound of formula (XII).

The compound of formula (XII) is reacted with a suitably selected oxidizing reagent such as OsO₄ and NMO, (CH₃)₃NO, and the like, in an organic solvent such as butanol, THF, water, and the like, or mixture thereof, to
10 yield the corresponding compound of formula (XIII).

The compound of formula (XIII) is reacted with a suitably selected oxidizing agent such as lead acetate, NaIO₄, and the like, in an organic solvent such as THF, dioxane, diethyl ether, and the like, to yield the corresponding
15 compound of formula (XIV).

The compound of formula (XIV) is reacted with a reducing agent such as NaBH₄, Zn(BH₄)₂, borane, and the like, in an organic solvent such as THF, diethyl ether, dioxane, and the like, at a temperature in the range of from about
20 -10°C to about room temperature, to yield the corresponding compound of formula (XV).

The compound of formula (XV) is reacted with a suitably selected protecting agent such as TBSCl TBSOTf, and the like, in the presence of a
25 base such as pyridine, 2,6-lutidine, and the like, in an organic solvent such as DCM, CHCl₃, 1,2-dichloroethane, and the like, at a temperature in the range of from about 0°C to about -78°C, to yield the corresponding compound of formula (XVI).

30 The compound of formula (XVI) is reacted under suitably selected oxidizing conditions such as Dess Martin per iodine reagent, Swer oxidation, Jones oxidation, and the like, in an organic solvent such as DCM, CHCl₃, 1,2

PRD2637WOPCT

dichloroethane, and the like, to yield the corresponding compound of formula (XVII).

5 The compound of formula (XVII) is reacted with a suitably substituted Grignard reagent, a compound of formula (XVIII), a known compound or compound prepared by known methods, in an organic solvent such as THF, diethyl ether, THF, and the like, at a temperature in the range of from about -78°C to about -10°C, to yield the corresponding compound of formula (XIX).

10 The compound of formula (XIX) is de-protected by reacting with a suitably selected reagent such as tetrabutyl ammonium fluoride, KF, HF •pyridine/pyridine, and the like, in an organic solvent such as THF, diethyl ether, dioxane, and the like, at a temperature in the range of from about 0°C to about room temperature, to yield the corresponding compound of formula (XX).

15

 The compound of formula (XX) is reacted under acidic condition, for example with a catalytic amount of an acid such as TsOH, H₂SO₄, HCl, and the like in an organic solvent such as THF, acetone, and the like, at room temperature, to yield the corresponding compound of formula (XXI).

20

 The compound of formula (XXI) is reacted with ethane-1,2-diol, a known compound, in the presence of a such as ethylorthoformate, methyl ortho formate, and the like, in the presence of an acid such as TsOH, H₂SO₄, HCl, and the like, in an organic solvent such as THF, dioxane, diethyl ether, and the like, to yield the corresponding compound of formula (XXII).

25

 The compound of formula (XXII) is reacted with a suitably selected compound of formula (XXIII), wherein M is Li, MgCl, MgBr or MgI, a known compound or compound prepared by known methods, in an organic solvent such as THF, dioxane, diethyl ether, and the like, to yield the corresponding compound of formula (XXIV).


30

PRD2637WOPCT

The compound of formula (XXIV) is reacted with an acid such as TsOH, HCl, sulfuric acid, and the like, in an organic solvent such as THF, acetonitrile, MeOH, EtOH, and the like, to yield the corresponding compound of formula (Ia).

5

Compounds of formula (I wherein R^2 and R^3 are taken together with the carbon atom to which they are bound to form 2-(3-methylene-tetrahydro-furanyl) may be prepared according to the process outlined in Scheme 2 below.



10

Scheme 2

Accordingly, a suitably substituted compound of formula (XXII), a compound prepared, for example, as described Scheme 1 above, is reacted with a suitably substituted compound of formula (XV), wherein W is a protecting group such as TBS, TES, TIPS, and the like, a known compound or compound prepared by known methods, in an organic solvent such as THF, dioxane, diethyl ether, and the like, at a temperature in the range of from about -10°C to about 30°C, to yield the corresponding compound of formula (XXVI).

15

20


The compound of formula (XXVI) is cyclized by reacting with a reagent such as methane sulphonyl chloride, TsCl, Tf_2O , and the like, in the presence of a phase transfer catalyst such as tetrabutyl ammonium fluoride and the like, preferably in the presence of from about one to about 30 equivalents of

PRD2637WOPCT

pyridine, in an organic solvent such as THF, diethyl ether, dioxane, and the like, to yield the corresponding compound of formula (XXVII).

The compound of formula (XXVII) is reacted with an acid such as TsOH, HCl, H₂SO₄, and the like, in an organic solvent such as acetone, THF, dioxane, and the like, at a temperature in the range of from about 0°C to about room temperature, to yield the corresponding compound of formula (Ib).

Compounds of formula (II) may be prepared according to the procedure as outlined in Scheme 3 below.



Scheme 3

Accordingly, a suitably substituted compound of formula (Ia) is reacted with an acid such as TsOH, HCl, H₂SO₄, and the like, according to known methods, to yield the corresponding compound of formula (II).

One skilled in the art will recognize that wherein a reaction step of the present invention may be carried out in a variety of solvents or solvent systems, said reaction step might also be carried out in a mixture of the suitable solvents or solvent systems. Where the processes for the preparation of the compounds according to the invention give rise to mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-D-tartaric acid and/or (+)-di-p-toluoyl-L-tartaric acid followed by

PRD2637WOPCT

fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.

5

During any of the processes for preparation of the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective
10 Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

15 The present invention includes within its scope **prodrugs** of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds which are readily convertible *in vivo* into the required compound. Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the treatment of the
20 various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound *in vivo* after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier,
25 1985.

For use in medicine, the salts of the compounds of this invention refer to non-toxic "**pharmaceutically acceptable salts**." Other salts may, however, be useful in the preparation of compounds according to this invention or of their
30 pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds include acid addition salts which may, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid,

PRD2637WOPCT

fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g., sodium or

- 5 potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts. Thus, representative pharmaceutically acceptable salts include the following:

- acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate,
 10 borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate,
 15 mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, pamoate (embonate), palmitate, pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, sulfate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide and valerate.

20

Representative acids and bases which may be used in the preparation of pharmaceutically acceptable salts include the following:

- acids including acetic acid, 2,2-dichloroacetic acid, acylated amino acids, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid,
 25 benzoic acid, 4-acetamidobenzoic acid, (+)-camphoric acid, camphorsulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic acid,
 30 D-glucuronic acid, L-glutamic acid, α -oxo-glutaric acid, glycolic acid, hipuric acid, hydrobromic acid, hydrochloric acid, (+)-L-lactic acid, ($\pm$)-DL-lactic acid, lactobionic acid, maleic acid, (-)-L-malic acid, malonic acid, ($\pm$)-DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-

PRD2637WOPCT

disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitric acid, pantoic acid, phosphoric acid, L-pyroglutamic acid, salicylic acid, 4-amino-salicylic acid, sebaic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid,
5 p-toluenesulfonic acid and undecylenic acid; and

bases including ammonia, L-arginine, benethamine, benzathine, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2-(diethylamino)-ethanol, ethanolamine, ethylenediamine, N-methyl-glucamine, hydrabamine, 1H-imidazole, L-lysine, magnesium hydroxide, 4-(2-hydroxyethyl)-morpholine,
10 piperazine, potassium hydroxide, 1-(2-hydroxyethyl)-pyrrolidine, secondary amine, sodium hydroxide, triethanolamine, tromethamine and zinc hydroxide.

The present invention further comprises pharmaceutical compositions containing one or more compounds of formula (I) and / or one or more
15 compounds of formula (II) with a pharmaceutically acceptable carrier. Pharmaceutical compositions containing one or more of the compounds of the invention described herein as the active ingredient can be prepared by intimately mixing the compound or compounds with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The
20 carrier may take a wide variety of forms depending upon the desired route of administration (e.g., oral, parenteral). Thus for liquid oral preparations such as suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, stabilizers, coloring agents and the like; for solid oral preparations, such as powders, capsules and
25 tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Solid oral preparations may also be coated with substances such as sugars or be enteric-coated so as to modulate major site of absorption. For parenteral administration, the carrier will usually consist of sterile water and other
30 ingredients may be added to increase solubility or preservation. Injectable suspensions or solutions may also be prepared utilizing aqueous carriers along with appropriate additives.

PRD2637WOPCT

To prepare the pharmaceutical compositions of this invention, one or more compounds of the present invention as the active ingredient is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide

5 variety of forms depending of the form of preparation desired for administration, e.g., oral or parenteral such as intramuscular. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus, for liquid oral preparations, such as for example, suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols,

10 flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such as, for example, powders, capsules, caplets, gelcaps and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the

15 most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. For parenterals, the carrier will usually comprise sterile water, through other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included. Injectable

20 suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, an amount of the active ingredient necessary to deliver an effective dose as described above. The

25 pharmaceutical compositions herein will contain, per unit dosage unit, e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like, of from about 50-100 mg and may be given at a dosage of from about 0.1-5.0 mg/kg/day, preferably from about 0.5-2.5 mg/kg/day. The dosages, however, may be varied depending upon the requirement of the patients, the severity of

30 the condition being treated and the compound being employed. The use of either daily administration or post-periodic dosing may be employed.

PRD2637WOPCT

Preferably these compositions are in unit dosage forms from such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, autoinjector devices or suppositories; for oral parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. Alternatively, the composition may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of material can be used for such enteric layers or coatings, such materials including a number of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

PRD2637WOPCT

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include, aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or
5 peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions, include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

10 The methods of treating of the present invention may also be carried out using a pharmaceutical composition comprising any of the compounds as defined herein and a pharmaceutically acceptable carrier. The pharmaceutical composition may contain between about 0.1 mg and 500 mg, preferably about 50 to 100 mg, of the compound, and may be constituted into any form suitable for
15 the mode of administration selected. Carriers include necessary and inert pharmaceutical excipients, including, but not limited to, binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings. Compositions suitable for oral administration include solid forms, such as pills, tablets, caplets, capsules (each including immediate release, timed release and
20 sustained release formulations), granules, and powders, and liquid forms, such as solutions, syrups, elixers, emulsions, and suspensions. Forms useful for parenteral administration include sterile solutions, emulsions and suspensions.

Advantageously, compounds of the present invention may be administered
25 in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery
30 system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

PRD2637WOPCT

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders; lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

The liquid forms in suitably flavored suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl-cellulose and the like. For parenteral administration, sterile suspensions and solutions are desired. Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.

To prepare a pharmaceutical composition of the present invention, a compound of formula (I) as the active ingredient is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration (e.g. oral or parenteral). Suitable pharmaceutically acceptable carriers are well known in the art. Descriptions of some of these pharmaceutically acceptable carriers may be found in The Handbook of Pharmaceutical Excipients, published by the American Pharmaceutical Association and the Pharmaceutical Society of Great Britain.

Methods of formulating pharmaceutical compositions have been described in numerous publications such as Pharmaceutical Dosage Forms: Tablets, Second Edition, Revised and Expanded, Volumes 1-3, edited by Lieberman et al; Pharmaceutical Dosage Forms: Parenteral Medications, Volumes 1-2, edited by Avis et al; and Pharmaceutical Dosage Forms:

PRD2637WOPCT

Disperse Systems, Volumes 1-2, edited by Lieberman et al; published by Marcel Dekker, Inc.

Compounds of this invention may be administered in any of the foregoing
5 compositions and according to dosage regimens established in the art whenever treatment of disorders as described herein is required.

The daily dosage of the products may be varied over a wide range from 0.01 to 1,000 mg per adult human per day. For oral administration, the
10 compositions are preferably provided in the form of tablets containing, 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.01 mg/kg to about 300 mg/kg of body weight
15 per day. Preferably, the range is from about 0.5 to about 5.0 mg/kg of body weight per day, most preferably, from about 1.0 to about 3.0 mg/kg of body weight per day. The compounds may be administered on a regimen of 1 to 4 times per day.

20 Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the mode of administration, the strength of the preparation, the mode of administration, and the advancement of the disease condition. In addition, factors associated with the particular patient being treated, including patient age, weight, diet and time of
25 administration, will result in the need to adjust dosages.

One skilled in the art will recognize that, both *in vivo* and *in vitro* trials using suitable, known and generally accepted cell and / or animal models are predictive of the ability of a test compound to treat or prevent a given disorder.

30

One skilled in the art will further recognize that human clinical trials including first-in-human, dose ranging and efficacy trials, in healthy patients

PRD2637WOPCT


and / or those suffering from a given disorder, may be completed according to methods well known in the clinical and medical arts.

The following Examples are set forth to aid in the understanding of the invention, and are not intended and should not be construed to limit in any way the invention set forth in the claims which follow thereafter.

In the Examples which follow, some synthesis products are listed as having been isolated as a residue. It will be understood by one of ordinary skill in the art that the term "residue" does not limit the physical state in which the product was isolated and may include, for example, a solid, an oil, a foam, a gum, a syrup, and the like.


Example 1

3'H-spiro-[[1,3]-dioxol-11,12-Dihydroxy-13-methyl-1,6,7,8,11,12,13,14,15,16-decahydro-2H-cyclopenta[a]phenanthrene-3,17- dione
(Compound #39)



A solution of 1,3 dioxolane-13-methyl-1,6,7,8,13,14,15,16-octahydro-2H-cyclopenta[a]phenanthrene-3,17-dione (30 g, 95.54 mmol) in t-butanol (600 mL) was prepared and OsO₄ (1 mL) was added along with NMO (45 gm). The resulting mixture was stirred at room temperature for 45 hours. Water (600 mL) and EtOAc (1200 mL) was added and the layers were separated. The aqueous layer was extracted with EtOAc (350 mL). The organic layers were washed with water, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting sticky oil was suspended in (100 mL) and hexanes (100 mL) and stirred. The solid was filtered and dried in vacuo to yield the title compound.

PRD2637WOPCT

MS = 347.18 (M+H⁺)**Example 2****6'-(2-Formyl-2-methyl-3-oxo-cyclopentyl)-4',6',7',8'-tetrahydro-3'H-spiro-
5 [[1,3]-dioxolane-2,2'-naphthalene]-5'-carbaldehyde (Compound #40)**


A solution of 1,3 dioxolane, 11-12 dihydroxy-13-Methyl-1,6,7,8,13,14,15,16-octahydro-2H-cyclopenta[a]phenanthrene-3,17-dione (15 g, 50.54 mmol) in THF (600 mL) was prepared and lead tetra acetate (28 g) were added along with pyridine (10 mL). The resulting mixture was stirred at room temperature for 5 hours. Aqueous solution of NaHCO₃ was added (600 mL) and EtOAc (1200 mL) was added and the layers were separated. The aqueous layer was extracted with EtOAc (350 mL). The organic layers were washed with water, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting sticky oil was purified by column chromatography eluting with 20 to 95% ethyl acetate/hexanes to yield the title compound as a white solid.

MS = 347.18 (M+H⁺)

PRD2637WOPCT

Example 3**2-Hydroxymethyl-3-(5'-hydroxymethyl-4',6',7',8'-tetrahydro-3'H-spiro[[1,3]dioxolane-2,2'-naphthalen]-6'-yl)-2-methyl-cyclopentanone**

5

(Compound #41)


A solution of 6'-(2-formyl-2-methyl-3-oxo-cyclopentyl)-4',6',7',8'-tetrahydro-3'H-spiro[[1,3]dioxolane-2,2'-naphthalene]-5'-carbaldehyde (5 g, 10 mmol) in THF (300 mL) was prepared and NaBH₄ (4 g) were added slowly and stirred at room temperature for 6 hours. Aqueous solution of NaHCO₃ was added (600 mL) and EtOAc (1200 mL) was added and the layers were separated. The aqueous layer was extracted with EtOAc (350 mL). The organic layers were washed with water, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting sticky oil was purified by column chromatography eluting with 20 to 100 % ethyl acetate/hexanes to yield the title compound as a white solid.

MS = 349.3 (M+H⁺)

PRD2637WOPCT

Example 4**2-(tert-Butyl-dimethyl-silanyloxymethyl)-3-(5'-hydroxymethyl-4',6',7',8'-tetrahydro-3'H-spiro[[1,3]dioxolane-2,2'-naphthalen]-6'-yl)-2-methyl-cyclopentanone (Compound #42)**

5




A solution of 2-hydroxymethyl-3-(5'-hydroxymethyl-4',6',7',8'-tetrahydro-3'H-spiro[[1,3]dioxolane-2,2'naphthalen]-6'-yl)-2-methyl-cyclopentanone (4 g, 10 mmol) in CH₂Cl₂ (300 mL) was prepared and cooled to -78°C and pyridine (4.1 mL) and TBSOTf (3.3 mL) were added slowly and stirred at -78°C temperature for 6 hours. An aqueous solution of NaHCO₃ was added (600 mL) and EtOAc (300 mL) was added and the layers were separated. The aqueous layer was extracted with EtOAc (350 mL). The organic layers were washed with water, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting crude compound was purified by column chromatography eluting with 20 to 80 % ethyl acetate/hexanes to yield the title compound as a crystalline white solid.

15

MS = 463.4 (M+H⁺)


PRD2637WOPCT

Example 5**6'-[2-(tert-Butyl-dimethyl-silanyloxymethyl)-2-methyl-3-oxo-cyclopentyl]-
4',6',7',8'-tetrahydro-3'H-spiro[[1,3]dioxolane-2,2'-naphthalene]-5'-
carbaldehyde (Compound # 43)**

A solution of 2-(tert-Butyl-dimethyl-silanyloxymethyl)-3-(5'-hydroxymethyl-4',6',7',8'-tetrahydro-3'H spiro[[1,3]-dioxolane-2,2'-naphthalen]-6'-yl)-2-methyl-cyclopentanone (2 g, 10 mmol) in CH₂Cl₂ (100mL) was prepared and cooled to -10°C and pyridine (2.1 mL) Dess Martine per iodine (4.8 mg) were added slowly and the reaction mixture stirred at room temperature for 9 hours. An aqueous solution of NaHCO₃ was added (600 mL) and EtOAc (300 mL) was added and the layers were separated. The aqueous layer was extracted with EtOAc (350mL). The organic layers were washed with water, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting crude compound was purified by column chromatography eluting with 20 to 80 % ethyl acetate/hexanes to yield the title compound as a crystalline white solid.

MS = 461.2 (M+H⁺)

PRD2637WOPCT

Example 6**3'H-spiro[[1,3]dioxolane-10-(4-Dimethylamino-phenyl)-12a-methyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-8H-11-oxa-naphtho[2,1 e]azulene-1,7-dione (Compound #44)**

Step 1: 2-(tert-Butyl-dimethyl-silanyloxymethyl)-3-{5'-[(4-dimethyl amino-phenyl)-hydroxy-methyl]-4',6',7',8'-tetrahydro-3'Hspiro[[1,3]dioxolane-2,2'-naphthalen]-6'-yl}-2-methyl-cyclopentanone:

10 A solution of 6'-[2-(tert-Butyl-dimethyl-silanyloxy methyl)-2-methyl-3-oxo-cyclopentyl]-4',6',7',8'-tetrahydro-3'H-spiro[[1,3]dioxolane-2,2'-naphthalene]-5'-carbaldehyde (1 g, 5 mmol) in THF (50 mL) was prepared and cooled to -78°C and N,N-dimethyl phenyl magnesium bromide (2.1 mL, 1M solution in THF) was added stirred at -78°C for 9 hours. Aqueous solution of NaHCO_3 was added (300 mL) and EtOAc (300 mL) was added and the layers were separated. The aqueous layer was extracted with EtOAc (350mL). The organic layers were washed with water, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting crude compound was purified by column chromatography eluting with 20 to 80 % ethyl acetate/hexanes to yield the title compound as a crystalline yellow solid.

MS = 347.18 ($\text{M}+\text{H}^+$)

^1H NMR (400 MHz, CDCl_3): δ 7.16 (2H, d, $J = 8.8$ Hz), 6.66 (2H, d, $J = 8.8$ Hz), 5.46 (1H, s), 5.41 (s, 1H), 3.71 [center of AB quartet, $J_{\text{AB}} = 12.0$, $\Delta\nu = 284$ Hz, $\delta_{\text{A}} = 4.05$, $\delta_{\text{B}} = 3.34$, 2H], 4.15-3.89 (m, 4H), 2.92 (6H, s), 2.76-2.69 (m, 1H), 2.59-2.42 (m, 3H), 2.38-2.29 (m, 1H), 2.26-2.11 (m, 2H), 2.06-1.91 (m, 2H), 1.89-1.64 (m, 5H), 1.13 (3H, s).

PRD2637WOPCT

Step 2:

A solution of 2-(tert-butyl-dimethyl-silanyloxymethyl)-3-{5'-[(4-dimethylamino-phenyl)-hydroxy-methyl]-4',6',7',8'-tetrahydro-3'H-spiro[[1,3]dioxolane-2,2'-naphthalen]-6'-yl}-2-methyl-cyclopentanone (1 g, 5.6 mmol) in THF (50 mL) was prepared and cooled to -10°C and then tetra butyl ammonium fluoride (6.1 mL) was added and the resulting mixture was stirred at -10°C for 12 hours. An aqueous solution of NaHCO_3 was added (300 mL) and EtOAc (300 mL) was added and the layers were separated. The aqueous layer was extracted with EtOAc (350mL). The organic layers were washed with water, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting crude compound was purified by column chromatography eluting with 20 to 80 % ethyl acetate/hexanes to yield the 3-{5'-[(4-Dimethylamino-phenyl)-hydroxy-methyl]-4',6',7',8'-tetrahydro-3'H-spiro[[1,3] dioxolane-2,2'-naphthalen]-6'-yl}-2-hydroxymethyl-2methylcyclopenta-none compound as a crystalline yellow solid.


$$\text{MS} = 467.2 (\text{M}+\text{H}^+)$$

Step 3:

A solution of 3-{5'-[(4-dimethylamino-phenyl)-hydroxy-methyl]-4',6',7',8'-tetrahydro-3'H-spiro[[1,3]dioxolane-2,2'-naphthalen]-6'-yl}-2-hydroxymethyl-2-methyl-cyclopentanone (1 g, 5.6 mmol) in THF (50 mL) was prepared and cooled to 0°C and then TsOH (0.1 g) was added and stirred at room temperature for 14 hours. An aqueous solution of NaHCO_3 was added (300 mL) and EtOAc (300 mL) was added and the layers were separated. The aqueous layer was extracted with EtOAc (350mL). The organic layers were washed with water, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting crude compound was purified by column chromatography eluting with 20 to 80 % ethyl acetate/hexanes to yield the title compound as a crystalline yellow solid.

$$\text{MS} = 450.56 (\text{M}+\text{H}^+)$$

PRD2637WOPCT

Example 7**10-(4-Dimethylamino-phenyl)-1-hydroxy-12a-methyl-1-prop-1-ynyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one (Compound #7)**

5

Step 1:

A solution of 2-(tert-Butyl-dimethyl-silanyloxymethyl)-3-{5'-[(4-dimethylamino-phenyl)-hydroxy-methyl]-4',6',7', 8'-tetrahydro-3'H-spiro[[1,3]dioxolane-2,2'-naphthalen]-6'-yl}-2-methyl-cyclopentanone (1 g, 5.6 mmol) in THF (50 mL) was prepared and cooled to 0°C and then TsOH (0.1 g) was added and the resulting mixture stirred at room temperature for 14 hours. An aqueous solution of NaHCO₃ was added (300 mL) and EtOAc (300 mL) was added and the layers were separated. The aqueous layer was extracted with EtOAc (350mL). The organic layers were washed with water, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting crude compound was purified by column chromatography eluting with 20 to 80 % ethyl acetate/hexanes to yield the 3'H-spiro[[1,3]dioxolane-10-(4-Dimethylamino-phenyl)-1-hydroxy-12a-methyl-1-prop-1-ynyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one compound as a crystalline yellow solid.

20

MS = 490.2 (M+H⁺)**Step 2:**

3'H-spiro[[1,3]dioxolane-10-(4-Dimethylamino-phenyl)-1-hydroxy-12a-methyl-1-prop-1-ynyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one (200 mg) in acetone (5 mL) was prepared and cooled to 0°C and then TsOH (0.001 g) was added and the resulting mixture

25


PRD2637WOPCT

stirred at room temperature for 5 hours. An aqueous solution of NaHCO_3 was added (100 mL) and EtOAc (100 mL) was added and the layers were separated. The aqueous layer was extracted with EtOAc (50mL). The organic layers were washed with water, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting crude compound was purified by column chromatography eluting with 20 to 80 % ethyl acetate/hexanes to yield the title compound as a crystalline yellow solid.

MS=446.2(M+H⁺)

10

Example 8
(Compound # 38)



Step 1:

A solution of tert-butyl-(3-iodo-but-3-enyloxy)-dimethyl-silane (312 mg, 1 mmol) in THF (5 mL) was prepared and cooled to -78°C and n-BuLi (3.5 mL, 1.6 M solution in hexanes) was added. The resulting mixture was stirred at -78°C for 3 min. To the reaction mixture was then added a solution of 3'H-spiro[[1,3]dioxolane-10-(4-dimethylamino-phenyl)-12a-methyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-8H-11-oxa-naphtho[2,1-e]azulene-1,7-dione (120 mg in 5 ml of THF) and the mixture stirred for 30 min. An aqueous solution of NaHCO_3 was added (300 mL) and EtOAc (300 mL) was added and the layers were separated. The aqueous layer was extracted with EtOAc (350mL). The organic layers were washed with water, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting crude compound was purified by column chromatography eluting with 20 to 80 % ethyl acetate/hexanes to yield the 1-{1-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-vinyl}-10-(4-dimethylamino-phenyl)-1-hydroxy-12a-methyl-

PRD2637WOPCT

2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one as a crystalline yellow solid.

MS = 636.2 (M+H⁺)

5 Step 2:

The compound prepared in Step 1 above (1 g, 5.6 mmol) in THF:pyridine (5ml:5mL) was prepared and cooled to -10°C and tetra butyl ammonium fluoride (6.1 mL) was added and the resulting mixture stirred at -10°C for 0.5 hours. Methane sulphonyl chloride (100 μ L) was added and the
10 resulting mixture stirred for additional 3 hours. An aqueous solution of NaHCO₃ was added (50 mL) and EtOAc (100 mL) was added and the layers were separated. The aqueous layer was extracted with EtOAc (50 mL). The organic layers were washed with water, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting crude compound was purified by
15 column chromatography eluting with 20 to 80 % ethyl acetate/hexanes to yield the title compound as a crystalline yellow solid.

MS = 503.30 (M+H⁺)


Step 3

20 The compound prepared in Step 2 above (200 mg) was dissolved in acetone (5 mL) was prepared and cooled to 0°C, then TsOH (0.001 g) was added and the resulting mixture stirred at room temperature for 5 hours. An aqueous solution of NaHCO₃ was added (100 mL) and EtOAc (100 mL) was added and the layers were separated. The aqueous layer was extracted with
25 EtOAc (50mL). The organic layers were washed with water, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting crude compound was purified by column chromatography eluting with 20 to 80 % ethyl acetate/hexanes to yield the title compound as a crystalline yellow solid.

MS = 446.2 (M+H⁺)

30

PRD2637WOPCT


Example 9**10-(4-Dimethylamino-phenyl)-1-hydroxy-1-isopropenyl-12a methyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1 e]azulen-7-one (Compound #1)**

5

The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 8.

MS = 460 (M+ H⁺)

10

Example 10**3'H-spiro[[1,3]dioxolane 12a-Methyl-10-(4-methylsulfanyl-phenyl)2,3,3a,3b,4,5,9,10,12, 12a-decahydro-8H-11-oxa-naphtho[2,1-e]azulene-1,7-dione (Compound # 51)**


15

The title compound was prepared as a white solid according to the procedure described in Example 6, 7 and 8 above, starting from the compound prepared as in Example 5.

MS = 453 (M+ H⁺)

20

PRD2637WOPCT

Example 11**3'H-spiro[[1,3]dioxolane 12a-Methyl-10-(4-methoxy-phenyl)****2,3,3a,3b,4,5,9,10,12, 12a-decahydro-8H-11-oxa-naphtho[2,1-e]azulene-1,7-dione (Compound # 45)**


5

The title compound was prepared as a white solid according to the procedure described in Example 6, starting from the compound prepared as in Example 5.

MS = 437.2 (M+ H⁺)

¹H NMR (400 MHz, CDCl₃): δ 7.15 (2H, d, J = 8.8 Hz), 6.67 (2H, d, J = 8.8 Hz), 5.77 (1H, s), 5.39 (1H, s), 5.09 (1H, s), 4.84 (1H, s), 3.85-3.77 (3H, m), 3.21 (1H, part of AB quartet), 2.93 (6H, s), 2.88-2.82 (1H, m), 2.71-2.51 (4H, m), 2.48-2.33 (3H, m), 2.31-2.22 (1H, m), 2.18-2.04 (2H, m), 1.98-1.78 (3H, m), 1.71-1.63 (m, 2H), 1.18 (s, 3H)

15

Example 12**1-Hydroxy-1-isopropenyl-12a-methyl-10-(4-methylsulfonyl-phenyl)-****2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one (Compound #2)**

20


PRD2637WOPCT

The title compound was prepared as a white solid according to the procedure described in Example 6 starting from the compound prepared as in Example 8.

MS = 451.2 (M+ H⁺)

5

Example 13
(Compound #2)




The title compound was prepared as a white solid according to the procedure described in Example 8, starting from the compound prepared as in Example 9.

MS = 447.25 (M+ H⁺)

¹H NMR (400 MHz, CDCl₃): δ 7.15 (2H, d, J = 8.8 Hz), 6.67 (2H, d, J = 8.8 Hz), 5.77 (1H, s), 5.39 (1H, s), 5.09 (1H, s), 4.84 (1H, s), 3.85-3.77 (3H, m), 3.21 (1H, part of AB quartet), 2.93 (6H, s), 2.88-2.82 (1H, m), 2.71-2.51 (4H, m), 2.48-2.33 (3H, m), 2.31-2.22 (1H, m), 2.18-2.04 (2H, m), 1.98-1.78 (3H, m), 1.71-1.63 (m, 2H), 1.18 (s, 3H).

Example 14
10-(4-Dimethylamino-phenyl)-1-ethynyl-1-hydroxy-12a-methyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H, 8H-11-oxa-naphtho[2,1-e]azulen-7-one (Compound #3)



PRD2637WOPCT


The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 6.

MS = 432.25 ($M + H^+$)

5

Example 15

1-Hydroxy-12a-methyl-10-(4-methylsulfanyl-phenyl)-1-pentafluoroethyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one (Compound #4)



10


The title compound was prepared as a white solid according to the procedure described in Example 7, starting from the compound prepared as in Example 6 and reacting with $LiCF_2CF_3$.

MS = 528.18

15

Example 16

1-Hydroxy-10-(4-methoxy-phenyl)-12a-methyl-1-(4-trifluoromethyl-phenylethynyl)-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one (Compound #6)



20

PRD2637WOPCT


The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 8.

MS = 563.2

5

Example 17

1-(4-tert-Butyl-phenylethynyl)-1-hydroxy-10-(4-methoxy-phenyl)-12a-methyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one (Compound #9)



10


The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 8.

MS = 551.2

15

Example 18

10-(4-Dimethylamino-phenyl)-12a-methyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-8H-11-oxa-naphtho[2,1-e]azulene-1,7-dione (Compound #10)



20

3'H-spiro[[1,3]dioxolane-10-(4-Dimethylamino-phenyl)-12a-methyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-8H-11-oxa-naphtho[2,1e]azulene-1,7-dione, prepared as in Example 6 above (50 mg) was dissolved in acetone (5 mL) was prepared and cooled to 0°C. TsOH (0.001 g) was added and the

PRD2637WOPCT

resulting mixture stirred at room temperature for 5 hours. An aqueous solution of NaHCO₃ was added (100 mL) and EtOAc (100 mL) was added and the layers were separated. The aqueous layer was extracted with EtOAc (50mL). The organic layers were washed with water, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting crude compound was purified by column chromatography eluting with 20 to 80 % ethyl acetate/hexanes to yield the title compound as a crystalline yellow solid.

MS = 406.2 (M+H⁺)


10

Example 19

12a-Methyl-10-(4-methylsulfanyl-phenyl)-1-phenylethynyl

3a,3b,4,5,9,10,12,12a-octahydro-3H,8H-11-oxa-naphtho[2,1-e]azulen-7-one

(Compound #11)



15

The title compound was prepared as a white solid according to the procedure described in Example 17 starting from the compound prepared as in Example 10.

MS = 493.2


20

25

PRD2637WOPCT

Example 20

1-Ethynyl-1-hydroxy-10-(4-methoxy-phenyl)-12a-methyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one
(Compound #12)



5


The title compound was prepared as a white solid according to the procedure described in Example 17 starting from the compound prepared as in Example 11.

MS = 419.3

10 ^1H NMR (300 MHz, CDCl_3): δ 7.25 (2H, d, J = 8.8 Hz), 6.85 (2H, d, J = 8.8 Hz), 5.80 (1H, s), 5.55 (1H, s), 3.79 (3H, s), 3.95-3.60 (AB quartet, J_{AB} = 12.0, 2H), 2.80-1.60 (14H, m), 2.60 (1H, s), 1.12 (3H, s).

Example 21

15 **3'H-spiro [1,3]dioxolane-10- α -(4-Methoxy-phenyl)-12a-methyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-8H-11-oxa-naphtho[2,1-e]azulene-1,7-dione**




20 The title compound was isolated as side product as in preparation described in Example 11

MS 437.2

PRD2637WOPCT

Example 22

1-Ethynyl-1-hydroxy-10-(4-methoxy-phenyl)-12a-methyl 2,3,3a, 3b
,4,5,9,10,12,12 a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one
(Compound #13)



5


The title compound was prepared as a white solid according to the procedure described in Example 17 starting from the compound prepared as in Example 21.

MS = 419.3

10 ^1H NMR (300 MHz, CDCl_3): δ 7.25 (2H, d, J = 8.8 Hz), 6.85 (2H, d, J = 8.8 Hz), 6.05 (1H, s), 5.75 (1H, s), 3.81 (3H, s), 3.80-3.20 (AB quartet, J_{AB} = 12.0, 2H), 2.80-1.60 (14H, m), 2.55 (1H, s), 1.10 (3H, s).

Example 23

15 **1-Hydroxy-10-(4-methoxy-phenyl)-12a-methyl-1-prop-1-ynyl-**
2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8 H-11-oxa-naphtho[2,1-e]azulen-
7-one: (Compound #14)



20 The title compound was prepared as a white solid according to the procedure described in Example 7, starting from the compound prepared as in Example 11.

MS = 433.3


PRD2637WOPCT

^1H NMR (300 MHz, CDCl_3): δ 7.25 (2H, d, J = 8.8 Hz), 6.85 (2H, d, J = 8.8 Hz), 5.70 (1H, s), 5.56 (1H, s), 3.69 (3H, s), 3.90-3.50 (AB quartet, J_{AB} = 12.0, δ_{A} = 3.90, δ_{B} = 3.60, 2H], 2.85-1.60 (14H, m), 1.70 (3H, s), 1.10 (3H, s).

5

Example 24

1-Hydroxy-10- α (4-methoxy-phenyl)-12a-methyl-1-prop-1-ynyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one (Compound #15)




10 The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 21.

MS = 433.2

15 ^1H NMR (300 MHz, CDCl_3): δ 7.28 (2H, d, J = 8.8 Hz), 6.91 (2H, d, J = 8.8 Hz), 6.05 (1H, s), 5.61 (1H, s), 3.79 (3H, s), 3.50 [center of AB quartet, J_{AB} = 12.0, $\Delta\nu$ = 180 Hz, δ_{A} = 3.80, δ_{B} = 3.20, 2H], 2.71-1.52 (14H, m), 1.49 (3H, s), 1.10 (3H, s).

Example 25

20 **1-Hydroxy-10-(4-methoxy-phenyl)-12a-methyl-1-phenylethynyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H, 8H-11-oxa-naphtho[2,1-e]azulen-7-one (Compound #16)**



PRD2637WOPCT

The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 11.


MS = 495.2

5

Example 26

1-Allyl-1-hydroxy-10-(4-methoxy-phenyl)-12a-methyl 2,3,3a,3b,4,5, 9, 10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one

(Compound #17)



10

The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 11.


MS = 435.2

15 ^1H NMR (300 MHz, CDCl_3): δ 7.25 (2H, d, $J = 8.8$ Hz), 6.88 (2H, d, $J = 8.8$ Hz), 6.05-5.80 (1H, m), 5.79 (1H, s), 5.51 (1H, s), 5.25-5.15 (2H, m), 3.91-3.48 (AB quartet, $J_{AB} = 12.0$, 2H), 3.80 (3H, s), 2.90-2.80 (1H, m), 2.60-1.60 (13H, m), 1.20 (3H, s).

PRD2637WOPCT

Example 27**1-Allyl-1-hydroxy-10 α -(4-methoxy-phenyl)-12a-methyl 2,3,3a,3b,4,5, 9, 10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one**

5

(Compound #18)


The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 21.

10

MS = 435.2

^1H NMR (300 MHz, CDCl_3): δ 7.25 (2H, d, J = 8.8 Hz), 6.90 (2H, d, J = 8.8 Hz), 6.05 (1H, s), 5.72 (1H, s), 5.81-5.68 (1H, m), 5.10 (1H, dd, J = 1.2, 6.8 Hz), 4.95 (1H, dd, J = 1.2, 12.0 Hz), 3.81 (3H, s), 3.40-3.15 (AB quartet, J_{AB} = 12.0, 2H), 2.85-2.71 (1H, m), 2.60-1.60 (13H, m), 1.18 (3H, s).

15

Example 28**1-Hydroxy-10-(4-methoxy-phenyl)-12a-methyl-1-trifluoroprop-1-ynyl- 2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one (Compound #19)**

20

PRD2637WOPCT


The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 11.

MS = 487.4 (M+H⁺)

5

Example 29

1-Hydroxy-10-(4-methoxy-phenyl)-12a-methyl-1-trifluoroprop-1-ynyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one (Compound #20)



10

The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 21.

MS = 487.4 (M+H⁺)


15

¹H NMR (400 MHz, CDCl₃): δ 7.22 (2H, d, J = 8.8 Hz), 6.89 (2H, d, J = 8.8 Hz), 6.10 (1H, s), 5.80 (1H, s), 3.82 (3H, s), 3.33 [center of AB quartet, J_{AB} = 12.4, Δν = 109 Hz, δ_A = 3.46, δ_B = 3.19, 2H], 2.92-1.61 (14H, m), 1.15 (3H, s).

Example 30

20

1-Hydroxy-10-(4-methoxy-phenyl)-12a-methyl-1-(4-trifluoromethylphenylethynyl)-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one (Compound #21)



PRD2637WOPCT


The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 11.

MS = 563.4 (M+H⁺)

5

Example 31

1-Hydroxy-10-(4-methoxy-phenyl)-12a-methyl-1-(4-trifluoro methyl phenylethynyl)-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one (Compound #22)



10


The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 21.

MS = 563.4 (M+H⁺)

15

Example 32

1-Hydroxy-10-(4-methoxy-phenyl)-12a-methyl-1-phenylethynyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one (Compound #23)



20

The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 21.

MS = 495.4 (M+H⁺)


PRD2637WOPCT

^1H NMR (300 MHz, CDCl_3): δ 7.39-7.20 (7H, m), 6.88 (2H, d, $J = 8.8$ Hz), 5.80 (1H, s), 5.60 (1H, s), 4.02-3.56 (AB quartet, $J_{\text{AB}} = 12.0$, 2H), 3.80 (3H, s), 2.90-1.60 (14H, m), 1.20 (3H, s).

5

Example 33

1-Hydroxy-1-[2-(2-hydroxy-ethyl)-allyl]-10-(4-methoxy-phenyl)-12a-methyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one



10 Step 1:

A solution of tert-butyl-(3-iodo-but-3-enyloxy)-dimethyl-silane (312 mg.) in THF (5 mL) was prepared and cooled to -78°C and then n-BuLi (3.5 mL, 1.6 M solution in hexanes) was added and the resulting mixture stirred at -78°C for 3 min. To the reaction mixture was then added a solution of 3'H-

15 spiro[[1,3]dioxolane-10-(4-methoxy-phenyl)-12a-methyl-

2,3,3a,3b,4,5,9,10,12,12a-decahydro-8H-11-oxa-naphtho[2,1-e]azulene-1,7-dione (120 mg in 5 mL of THF) and the resulting mixture was stirred for 30 min.

An aqueous solution of NaHCO_3 was added (300 mL) and EtOAc (300 mL) was added and the layers were separated. The aqueous layer was extracted with

20 EtOAc (350 mL). The organic layers were washed with water, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting crude compound was purified by column chromatography eluting with 20 to 80 % ethyl acetate/hexanes to yield the 3'H-spiro [1,3] dioxolane -1-[2-[2-(tert-Butyl-dimethyl-silyloxy)-ethyl]-allyl]-1-hydroxy-10-(4-methoxy-phenyl)-12a-methyl-2,3,3a,3b,4,5,9,10,12,12a decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one as a crystalline yellow solid.

PRD2637WOPCT

Step 2:


A solution of 3'H-spiro [1,3]dioxolane -1-{2-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-allyl}-1-hydroxy-10-(4-methoxy-phenyl)-12a-methyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one (0.1 g) in THF (50 mL) was prepared and cooled to -10°C . Tetra butyl ammonium fluoride (1.3mL) was added and the resulting mixture was stirred at -10°C for 12 hours. An aqueous solution of NaHCO_3 was added (30 mL) and EtOAc (300 mL) was added and the layers were separated. The aqueous layer was extracted with EtOAc (35mL). The organic layers were washed with water, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting crude compound was purified by column chromatography eluting with 20 to 80 % ethyl acetate/hexanes to yield the 3'H-spiro [1,3]dioxolane -1-{2-[2-(hydroxy)-ethyl]-allyl}-1-hydroxy-10-(4-methoxy-phenyl)-12a-methyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one compound as a crystalline yellow solid.

Step 3:

3'H-spiro [1,3]dioxolane -1-{2-[2-(hydroxy)-ethyl]-allyl}-1-hydroxy-10-(4-methoxy-phenyl)-12a-methyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one ether prepared as in Step 2 above (20 mg) was dissolved in acetone (5 mL) was prepared and cooled to 0°C . TsOH (0.001 g) was added and the resulting mixture stirred at room temperature for 5 hours. An aqueous solution of NaHCO_3 was added (100 mL) and EtOAc (100 mL) was added and the layers were separated. The aqueous layer was extracted with EtOAc (50mL). The organic layers were washed with water, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting crude compound was purified by column chromatography eluting with 20 to 80 % ethyl acetate/hexanes to yield the title compound as a crystalline yellow solid.

MS = 479.2 ($\text{M}+\text{H}^+$)


PRD2637WOPCT

Example 34**12a-Methyl-10-(4-methylsulfanyl-phenyl) 2,3,3a,3b,4,5,9,10,12, 12a-decahydro- 8H-11-oxa-naphtho[2,1- e]azulene-1,7-dione (Compound #25)**

- 5 The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 10.

MS = 409.2

10

Example 35**1-Acryloyl-1-hydroxy-12a-methyl-10-(4-methylsulfanyl-phenyl) 2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulene-7-one**

15 Step 1:

- A solution of 1-methoxyallene (0.3 ml, 1 mmol) in THF (5 mL) was prepared and cooled to -78°C and then n-BuLi (3.5 mL, 1.6 M solution in hexanes) was added and the resulting mixture stirred at -78°C for 3 min. To the reaction mixture was then added a solution of 3'H-spiro[[1,3]dioxolane-10-
- 20 (4-4-methylsulfanyl--phenyl)-12a-methyl-2,3,3a,3b,4,5,9, 10,12,12a-decahydro-8H-11-oxa-naphtho[2,1-e]azulene-1,7-dione (120 mg in 5 ml of THF) prepared as in Example 10 above, and the resulting mixture stirred for 30 min. An aqueous solution of NaHCO_3 was added (300 mL) and EtOAc (300 mL) was added and the layers were separated. The aqueous layer was extracted with

PRD2637WOPCT


EtOAc (350mL). The organic layers were washed with water, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting crude compound was purified by column chromatography eluting with 20 to 80 % ethyl acetate/hexanes to yield 3'H-spiro [1,3]dioxolane1-Hydroxy-1-(1-methoxy-
5 propa-1,2-dienyl)-12a-methyl-10-(4-methylsulfanyl-phenyl)-
2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one.

Step 2:

- 10 The title compound was prepared as a white solid according to the procedure described in Example 7, starting from the compound prepared in a step 1 above.

MS = 464.2

15


Example 36**10-(4-Methoxy-phenyl)-12a-methyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-8H-11-oxa-naphtho[2,1-e]azulene-1,7-dione (Compound #28)**

- 20 The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 11.

MS = 393.2

- 25 ^1H NMR (400 MHz, CDCl_3): δ 7.22 (2H, d, J = 8.8 Hz), 6.89 (2H, d, J = 8.8 Hz), 5.80 (1H, s), 5.36 (1H, s), 3.75 [center of AB quartet, J_{AB} = 12.1, $\Delta\nu$ = 299 Hz, δ_A = 4.13, δ_B = 3.38, 2H], 3.80 (3H, s), 2.92-1.56 (14H, m), 1.18 (3H, s).


PRD2637WOPCT

Example 37**10- α -(4-Methoxy-phenyl)-12a-methyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-8H-11-oxa-naphtho[2,1-e]azulene-1,7-dione (Compound #29)**

- 5 The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 11.

MS = 393.2

10

Example 38**1-Hydroxy-1-isopropenyl-10-(4-methanesulfonyl-phenyl)-12a-methyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one (Compound #30)**

- 15 1-Hydroxy-1-isopropenyl-12a-methyl-10-(4-methylsulfonyl-phenyl)-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one, prepared as in Example 12 above, (10 mg) dissolved in ethyl acetate (5 mL) was prepared and cooled to 0°C. Oxone® (100 mg) was added and the resulting mixture stirred at room temperature for 1 hours. An aqueous solution
- 20 of NaHCO₃ was added (100 mL) and EtOAc (100 mL) was added and the layers were separated. The aqueous layer was extracted with EtOAc (50mL). The organic layers were washed with water, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting crude compound

PRD2637WOPCT


was purified by column chromatography eluting with 20 to 80 % ethyl acetate/hexanes to yield the title compound as a crystalline yellow solid.

MS = 484.2 ($M+H^+$)

5

Example 39

10-(4-Dimethylamino-phenyl)-1-hydroxy-12a-methyl-1-phenyl ethynyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one (Compound #31)



10


The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 6.

MS = 507.28

15

Example 40

10-(4-Dimethylamino-phenyl)-1-(2-fluoro-phenylethynyl)-1-hydroxy-12a-methyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one (Compound #32)



20

The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 6.


PRD2637WOPCT

MS = 527.3.28, LC-MS 525 (M⁺)

¹H NMR (400 MHz, CDCl₃): δ 7.38-7.26 (2H, m), 7.20 (2H, d, J = 8.7 Hz), 7.12-6.99 (2H, m), 6.98 (2H, d, J = 5.34), 5.76 (1H, s), 5.58 (s, 1H), 3.88 [center of AB quartet, J_{AB} = 11.7, Δν = 83 Hz, δ_A = 3.98, δ_B = 3.77, 2H], 2.94 (6H, s), 2.88-2.68 (m, 3H), 2.51-2.27 (m, 6H), 2.19-2.11 (m, 1H), 1.97 (OH, s), 1.85-1.61 (m, 4H), 1.21 (3H, s).

Example 41

10 **10-(4-Dimethylamino-phenyl)-1-(3-fluoro-phenylethynyl)-1-hydroxy-12a-methyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one (Compound #34)**




The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 6.

MS = 527.3.28

Example 42

20 **10-(4-Dimethylamino-phenyl)-1-(4-fluoro-phenylethynyl)-1-hydroxy-12a-methyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one (Compound #35)**



PRD2637WOPCT


The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 6.

MS = 527.3.28

5

Example 43

1-(3,5-Difluoro-phenylethynyl)-10-(4-dimethylamino-phenyl)-1-hydroxy-12a-methyl-2,3,3a,3b,4,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one (Compound # 36)



10


The title compound was prepared as a white solid according to the procedure described in Example 7 starting from the compound prepared as in Example 6.

MS = 544.3.21

15

Example 44

10-(4-Dimethylamino-phenyl)-1-hydroxy-12a-methyl-1-penta fluoroethyl 2,3,3a, 3b,4 ,5,9,10,12,12a-decahydro-1H,8H-11-oxa-naphtho[2,1-e]azulen-7-one (Compound #37):



20

PRD2637WOPCT

The title compound was prepared as a white solid according to the procedure described in Example 15 starting from the compound prepared as in Example 6.

MS = 526. 13

5 ^1H NMR (400 MHz, CDCl_3): δ 7.15 (2H, d, J = 8.8 Hz), 6.67 (2H, d, J = 8.8 Hz), 5.76 (1H, s), 5.77 (1H, s), 5.48 (1H, s), 4.09-4.03 (1H, m), 3.68-3.61 (1H, m), 2.94 (6H, s), 2.91-2.86 (1H, m), 2.72-2.58 (2H, m), 2.58-2.37 (4H, m), 2.34-2.20 (2H, m), 1.96-1.77 (3H, m), 1.76-1.68 (2H, m), 1.26 (3H, s).

10

Example 45

T47D human breast cancer cells assay

T47D human breast cancer cells were grown in RPMI medium without phenol red (Invitrogen) containing 10% (v/v) heat-inactivated fetal bovine serum (FBS; Hyclone), 1% (v/v) penicillin-streptomycin (Invitrogen), 1% (w/v) glutamine (Invitrogen), and 10 mg/mL insulin (Sigma). Incubation conditions were 37°C in a humidified 5% (v/v) carbon dioxide environment.

The cells were plated in 96-well tissue culture plates at 10,000 cells per well in assay medium [RPMI medium without phenol red (Invitrogen) containing 5% (v/v) charcoal-treated FBS (Hyclone) and 1% (v/v) penicillin-streptomycin (Invitrogen)]. Two days later, the medium was decanted and test compound or control were added at a final concentration of 0.1% (v/v) dimethyl sulfoxide in fresh assay medium. Twenty-four hours later, an alkaline phosphatase assay was performed using a SEAP kit (BD Biosciences Clontech, Palo Alto, CA). Briefly, the medium was decanted and the cells were fixed for 30 minutes at room temperature with 5% (v/v) formalin (Sigma). The cells were washed once with room temperature Hank's buffered saline solution (Invitrogen). Equal volumes (0.05 mL) of 1X Dilution Buffer, Assay Buffer and 1:20 substrate/enhancer mixture were then added. After 1 hour incubation at room temperature in the dark, the lysate was transferred to a white 96-well plate (Dynex) and luminescence was read using a LuminoSkan Ascent (Thermo Electron, Woburn, MA).

PRD2637WOPCT

Example 46**A549 Human Lung Cell Assay**

A549 Human lung carcinoma cells were grown in F-12K Nutrient Mixture containing 10% (v/v) fetal bovine serum (FBS; Invitrogen), 2 mM glutamine and
5 0.15% sodium dicarbonate (Invitrogen).

A549 cells were split 1 to 3 in 175cm tissue culture flask. The cells were incubated at 37°C in CO₂ incubator until the cells were 95% confluent (typically 24-30 hours).

10

The following solutions were prepared in sterile tubes: (a) Solution A : 1.5 µg/ml of DNA in 8.5 ml OPTI-MEM I Reduced Serum Medium. (GIBCO cat# 31985) and (b) Solution B: 6 µl/ml of DMRIE-C Reagent into 8.5 µl OPTI-MEM I. The two solutions were combined and mixed gently, then incubated at room
15 temperature for 40 minutes.

The A549 cells prepared above were washed with 100 µl of OPTI-MEM I. The medium was removed and 17ml of the lipid-DNA complex solution was overlayed onto cells. The cells ere then incubated for 16h at 37°C in CO₂
20 incubator. The DNA-containing medium was removed and 30 ml of growth medium was added. (5%Charcoal treated FBS) After 5-6h, the cells were seeded in a 96 well plate and the cells incubated overnight at 37°C in CO₂ incubator.

25 To each well was then added 5 µl of test compounds and the cells incubated at 37°C for 10 min. 5 µL of dexamathasone (CAS [50-02-2]), was then added to each well for challenger and the cells incubated at 37°C in CO₂ incubator for 24h. 100 µl of Luc-assay buffer was then added into each cell well and the cells incubated for 30 min at room temperature. A 150 µL sample
30 from each well was then transferred into a DYNEX Microlitel plate and read on Top-counter.

PRD2637WOPCT

Representative compounds of the present invention were tested according to the procedures described in Examples 45 and 46 above, with results as listed in Table 2 below.

5

Table 2: Biological Results

Compound No.	A 549 IC₅₀ (nM)	T47D IC₅₀ (nM)
1	50.07	0.4
2	58.19	5.12
3	132.92	7
4	68.71	33.25
5	7.06	54
6	108.98	83
7	16.17	115.7
9	625.72	264
10	>3000	1800
11	>3000	>1000
12	117.92	>1000
13	367.04	>1000
14	46	>1000
15	583.43	>1000
16	>3000	>1000
17	114.17	>1000
18	>3000	>1000
19	>3000	>1000
20	>3000	>1000
21	>1000	>1000
22	>3000	>1000
23	237.46	260
24	771.03	176, 130
25	1317.4	
26	2313.96	
27	41.52	
28	>3000	
29	>3000	
30	>1000	
31		78

PRD2637WOPCT

32		48
34		122
35		17
36		160
37		42
38		1.1

Example 47


As a specific embodiment of an oral composition, 100 mg of the compound #5 is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size O hard gel capsule.

While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.

PRD2637WOPCT

We Claim:

1. A compound of formula (I)



- 5 R^1 is selected from the group consisting of $-NR^A R^B$, $-O-R^A$, $-S-R^A$ and $-SO_2-R^A$; wherein R^A and R^B are each independently selected from the group consisting of hydrogen and C_{1-4} alkyl;

- R^2 is selected from the group consisting of C_{1-4} alkyl, $-C_{1-4}$ alkyl-OH, halogenated C_{1-4} alkyl, C_{2-4} alkenyl, $-C_{2-4}$ alkenyl-OH, $-C_{2-4}$ alkenyl- CF_3 , C_{2-4} alkynyl, $-C_{2-4}$ alkynyl- CF_3 , $-C_{2-4}$ alkynyl-phenyl, $-C(O)-C_{2-4}$ alkyl, $-C(O)-C_{2-4}$ alkenyl and $-C(O)-phenyl$; wherein the phenyl, whether alone or as part of a substituent group, is optionally substituted with one to two substituents independently selected from the group consisting of halogen, C_{1-4} alkyl, fluorinated C_{1-4} alkyl, C_{1-4} alkoxy, fluorinated C_{1-4} alkoxy, cyano, nitro, amino, C_{1-4} alkylamino and $di(C_{1-4}alkyl)amino$;

- 15 R^3 is $-OH$;

alternatively, R^2 and R^3 are taken together with the carbon atom to which they are bound to form $C(O)$ or 2-(3-methylene-tetrahydro-furanyl);
or a pharmaceutically acceptable salt, ester or prodrug thereof.

- 20 2. A compound as in Claim 1, wherein

R^1 is selected from the group consisting of $NR^A R^B$, $-OR^A$, $-SR^A$ and $-SO_2-R^A$; wherein R^A and R^B are each independently selected from the group consisting of hydrogen and C_{1-2} alkyl;

- R^2 is selected from the group consisting of C_{1-4} alkyl, fluorinated C_{1-4} alkyl, $-C_{1-4}$ alkyl-OH, C_{2-4} alkenyl, $-C_{2-4}$ alkenyl-OH, $-C_{2-4}$ alkenyl- CF_3 , C_{2-4} alkynyl, $-C_{2-4}$ alkynyl- CF_3 , $-C_{2-4}$ alkynyl-phenyl, $-C(O)-C_{2-4}$ alkyl, and $-C(O)-C_{2-4}$ alkenyl; wherein the phenyl is optionally substituted with one to two substituents

PRD2637WOPCT

independently selected from the group consisting of halogen, C₁₋₄alkyl, fluorinated C₁₋₄alkyl, C₁₋₄alkoxy and fluorinated C₁₋₄alkoxy;

R³ is -OH;

- alternatively, R² and R³ are taken together with the carbon atom to which
 5 they are bound to form C(O) or 2-(3-methylene-tetrahydro-furanyl);
 or a pharmaceutically acceptable salt, ester or prodrug thereof.

3. A compound as in Claim 2, wherein

- R¹ is selected from the group consisting of NR^AR^B, -OR^A, -SR^A and -
 10 SO₂-R^A; wherein R^A and R^B are each independently selected from C₁₋₂alkyl;

- R² is selected from the group consisting of fluorinated C₁₋₃alkyl, C₂₋₄alkenyl, -C₂₋₄alkenyl-OH, C₂₋₄alkynyl; -C₂₋₄alkynyl-CF₃, -C₂₋₄alkynyl-phenyl, and -C(O)-C₂₋₄alkenyl; wherein the phenyl is optionally substituted with one to two substituents independently selected from the group consisting of halogen, C₁₋₄alkyl and fluorinated C₁₋₃alkyl;
 15

R³ is -OH;

alternatively, R² and R³ are taken together with the carbon atom to which they are bound to form C(O) or 2-(3-methylene-tetrahydro-furanyl);
 or a pharmaceutically acceptable salt, ester or prodrug thereof.

20

4. A compound as in Claim 3, wherein

R¹ is selected from the group consisting of dimethylamino, methoxy, methylthio and methylsulfonyl;

- R² is selected from the group consisting of -CF₂-CF₃, -CH(=CH₂)-CH₃, -CH₂-CH=CH₂, -CCH, -CC-CH₃, -CC-CF₃, -CC-phenyl, -CC-(4-trifluoromethyl-phenyl), -CC-(4-t-butyl-phenyl), -CC-(2-fluor-phenyl), -CC-(3-fluoro-phenyl), -CC-(4-fluoro-phenyl), -CC-(3,5-difluoro-phenyl), -CH(=CH₂)-CH₂-CH₂-OH and -C(O)-CH=CH₂;
 25

R³ is -OH;

- alternatively, R² and R³ are taken together with the carbon atom to which they are bound to form C(O) or 2-(3-methylene-tetrahydro-furanyl);
 or a pharmaceutically acceptable salt, ester or prodrug thereof.

30

PRD2637WOPCT

5. A compound as in Claim 4, wherein
R¹ is selected from the group consisting of dimethylamino, methoxy and methylthio;
R² is selected from the group consisting of -CF₂-CF₃, -CH(=CH₂)-CH₃, -
5 CCH and -CC-CH₃;
R³ is -OH;
or a pharmaceutically acceptable salt thereof.
6. A compound as in Claim 4, wherein
10 R¹ is selected from the group consisting of dimethylamino, methoxy and methylthio;
R² is selected from the group consisting of -CF₂-CF₃, -CH(=CH₂)-CH₃, -
CCH, , -CC-phenyl, -CC-(2-fluoro-phenyl), -CC-(4-fluoro-phenyl) and -CC-(4-
trifluoromethyl-phenyl);
15 R³ is -OH;
alternatively, R² and R³ are taken together with the carbon atom to which
they are bound to form 2-(3-methylene-tetrahydro-furanyl);
or a pharmaceutically acceptable salt thereof.
- 20 7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1.
8. A pharmaceutical composition made by mixing a compound of Claim 1
and a pharmaceutically acceptable carrier.
25
9. A process for making a pharmaceutical composition comprising mixing a
compound of Claim 1 and a pharmaceutically acceptable carrier.
10. A method of treating a disorder mediated by a progesterone or
30 glucocorticoid receptor, comprising administering to a subject in need thereof a
therapeutically effective amount of the compound of Claim 1.

PRD2637WOPCT

11 A method of contraception comprising administering to a subject in need thereof a therapeutically effective amount of the compound of Claim 1.

12. The method of Claim 10, wherein the disorder mediated by the
5 progesterone receptor is selected from the group consisting of secondary amenorrhea; dysfunctional bleeding; uterine leiomyomata; endometriosis; polycystic ovary syndrome; carcinoma of the endometrium, carcinoma of the ovary, carcinoma of the breast, carcinoma of the colon, carcinoma of the prostate, adenocarcinomas of the ovary, adenocarcinomas of the breast,
10 adenocarcinomas of the colon, adenocarcinomas of the prostate and side effects of cyclic menstrual bleeding.


13. The method of Claim 10, wherein the disorder mediated by the glucocorticoid receptor is selected from the group consisting of Type II diabetes
15 mellitus, impaired oral glucose tolerance, elevated blood glucose levels and Syndrome X.

14. A method of treating a disorder mediated by a progesterone or glucocorticoid receptor comprising administering to a subject in need thereof a
20 therapeutically effective amount of the composition of Claim 7.

15. The use of a compound as in Claim 1 for the preparation of a medicament for treating: (a) secondary amenorrhea; (b) dysfunctional bleeding; (c) uterine leiomyomata; (d) endometriosis; (e) polycystic ovary syndrome; (f)
25 carcinoma of the endometrium, (g) carcinoma of the ovary, (h) carcinoma of the breast, (i) carcinoma of the colon, (j) carcinoma of the prostate, (k) adenocarcinomas of the ovary, (l) adenocarcinomas of the breast, (m) adenocarcinomas of the colon, (n) adenocarcinomas of the prostate, (o) side effects of cyclic menstrual bleeding, (p) Type II diabetes mellitus, (q) impaired
30 oral glucose tolerance, (r) elevated blood glucose levels, (s) Syndrome X or (t) for contraception, in a subject in need thereof.

16. A compound of formula (II)

PRD2637WOPCT



R^1 is selected from the group consisting of $-NR^A R^B$, $-O-R^A$, $-S-R^A$ and $-SO_2-R^A$; wherein R^A and R^B are each independently selected from the group consisting of hydrogen and C_{1-4} alkyl;

- 5 R^2 is selected from the group consisting of C_{1-4} alkyl, $-C_{1-4}$ alkyl-OH, halogenated C_{1-4} alkyl, C_{2-4} alkenyl, $-C_{2-4}$ alkenyl-OH, $-C_{2-4}$ alkenyl- CF_3 , C_{2-4} alkynyl, $-C_{2-4}$ alkynyl- CF_3 , $-C_{2-4}$ alkynyl-phenyl, $-C(O)-C_{2-4}$ alkyl, $-C(O)-C_{2-4}$ alkenyl and $-C(O)-phenyl$; wherein the phenyl, whether alone or as part of a substituent group, is optionally substituted with one to two substituents
- 10 independently selected from the group consisting of halogen, C_{1-4} alkyl, fluorinated C_{1-4} alkyl, C_{1-4} alkoxy, fluorinated C_{1-4} alkoxy, cyano, nitro, amino, C_{1-4} alkylamino and $di(C_{1-4}alkyl)amino$;
- or a pharmaceutically acceptable salt, ester or prodrug thereof.

- 15 17. A compound as in Claim 16, wherein

R^1 is selected from the group consisting of $-SR^A$ and $-SO_2-R^A$; wherein R^A and R^B are each independently selected from the group consisting of hydrogen and C_{1-2} alkyl;

- R^2 is selected from the group consisting of C_{1-4} alkyl, fluorinated C_{1-4} alkyl,
- 20 $-C_{1-4}$ alkyl-OH, C_{2-4} alkenyl, $-C_{2-4}$ alkenyl-OH, $-C_{2-4}$ alkenyl- CF_3 , C_{2-4} alkynyl, $-C_{2-4}$ alkynyl- CF_3 , $-C_{2-4}$ alkynyl-phenyl, $-C(O)-C_{2-4}$ alkyl, and $-C(O)-C_{2-4}$ alkenyl;
- wherein the phenyl is optionally substituted with one to two substituents independently selected from the group consisting of halogen, C_{1-4} alkyl, fluorinated C_{1-4} alkyl, C_{1-4} alkoxy and fluorinated C_{1-4} alkoxy;
- 25 or a pharmaceutically acceptable salt, ester or prodrug thereof.

18. A compound as in Claim 17, wherein


PRD2637WOPCT

R^1 is selected from the group consisting of $-SR^A$; wherein R^A is selected from C_{1-3} alkyl;

R^2 is selected from the group consisting of $-CC$ -phenyl; wherein the phenyl is optionally substituted with one to two substituents independently selected from the group consisting of halogen, C_{1-4} alkyl and fluorinated C_{1-3} alkyl;

or a pharmaceutically acceptable salt, ester or prodrug thereof.

19. A compound as in Claim 18, selected from the group consisting of the compound of formula (IIa)



and pharmaceutically acceptable salts, esters and prodrugs thereof.